Woman and Man | 18 years and more
- | Country :
- France
- | organs :
- Tumeurs stromales digestives (GIST)
- | Specialty :
- Thérapies Ciblées
Extract
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment.
Scientific Abstract
en cours d'intégration;